Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Artiva Biotherapeutics, Inc. (ARTV)
USD9.70
+0.35 (+3.69%)
US NASDAQ Healthcare Biotechnology
Address
5505 Morehouse Drive 92121
San Diego, CA, US
San Diego, CA, US
CEO
Fred Aslan
Website
artivabio.com
IPO
2024-07-19
CIK 1817241 ISIN US04317A1079
Description
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
News Sentiment (7d)
Based on only 1 article — low confidence
- Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year? Zacks Investment Research
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD9.70
+0.35 (+3.69%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
575.8K
Beta
2.40
Float Shares
6.00M
Free Float %
24.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -13.02% | +0.65% | +59.91% | +179.95% | +197.54% | +153.85% | +418.57% | -9.25% | -9.25% | -9.25% | -9.25% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (4 ratings, all time)
Buy
Price Targets & DCF
Current price
9.70
Low
35.00
+261.0%
Consensus
35.00
+261.0%
Median
35.00
+261.0%
High
35.00
+261.0%
DCF (Unlevered)
0.64
-93.4%
DCF (Levered)
0.64
-93.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
35.00
+261.0%
|
| Last Quarter | 1 |
35.00
+261.0%
|
| Last Year | 1 |
35.00
+261.0%
|
| All Time | 3 |
25.33
+161.3%
|
Quality scores
Altman Z-Score
2.23
Grey zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%+34.0% ★ Q1'26: -14.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-702.2% Q1'26: -862.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.3% ★ Q1'26: +1.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.12× Q1'26: -0.11× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 EPS Ana. |
Dec 2027 4 EPS Ana. |
Dec 2028 5 Rev. Ana. 5 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
251.0K
est: 275.3K (-8.8%)
|
—
|
—
— – —
|
—
— – —
|
1.68M
1.68M – 1.68M
|
41.09M
41.09M – 41.09M
+2,345.8% YoY
|
203.05M
203.05M – 203.05M
+394.2% YoY
|
| EBITDA |
-64.85M
est: -156.8K (-41,249.8%)
|
-88.01M
|
—
— – —
|
—
— – —
|
-957.0K
-957.0K – -957.0K
|
-23.41M
-23.41M – -23.41M
-2,345.8% YoY
|
-115.66M
-115.66M – -115.66M
-394.2% YoY
|
| EBIT |
-67.28M
est: -160.6K (-41,804.3%)
|
-90.61M
|
—
— – —
|
—
— – —
|
-979.7K
-979.7K – -979.7K
|
-23.96M
-23.96M – -23.96M
-2,345.8% YoY
|
-118.41M
-118.41M – -118.41M
-394.2% YoY
|
| Net Income |
-58.49M
est: -135.97M (+57.0%)
|
-83.87M
est: -83.87M (+0.0%)
|
-74.32M
-92.87M – -55.77M
+11.4% YoY
|
-115.26M
-124.07M – -46.45M
-55.1% YoY
|
-84.19M
-132.16M – -36.22M
+27.0% YoY
|
-67.47M
-67.47M – -67.47M
+19.9% YoY
|
-28.40M
-28.40M – -28.40M
+57.9% YoY
|
| SGA |
17.21M
est: 4.44M (+287.6%)
|
20.27M
|
—
— – —
|
—
— – —
|
27.08M
27.08M – 27.08M
|
662.36M
662.36M – 662.36M
+2,345.8% YoY
|
3.27B
3.27B – 3.27B
+394.2% YoY
|
| EPS |
-5.20
est: -5.57 (+6.7%)
|
-3.43
est: -3.43 (-0.1%)
|
-3.03
-3.80 – -2.28
+11.7% YoY
|
-3.31
-5.08 – -1.90
-9.2% YoY
|
-3.28
-5.41 – -1.48
+0.6% YoY
|
-2.76
-2.76 – -2.76
+16.0% YoY
|
-1.16
-1.16 – -1.16
+57.9% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-08 | HC Wainwright & Co. | Buy | Buy | Maintain |
| 2026-05-04 | Needham | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-77.86M
OE per share TTM
-3.18
Owner's Yield
-28.97%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
237.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
7
Total invested
2.01M
Insider transactions (90d)
0
Beneficial owners (>5%)
24
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Peter Kolchinsky | 9.85M | 42.30% | — | 9.85M | — | 9.85M | HC, IN | United States | 2024-07-29 | ↗ |
| 2 | RA Capital Management, L.P. | 9.85M | 42.30% | — | 9.85M | — | 9.85M | IA, PN | Delaware | 2024-07-29 | ↗ |
| 3 | Rajeev Shah | 9.85M | 42.30% | — | 9.85M | — | 9.85M | HC, IN | United States | 2024-07-29 | ↗ |
| 4 | RA Capital Healthcare Fund, L.P. | 8.69M | 37.30% | — | 8.69M | — | 8.69M | PN | Delaware | 2024-07-29 | ↗ |
| 5 | GC Corp. | 4.57M | 19.60% | — | 4.57M | — | 4.57M | HC | — | 2024-07-29 | ↗ |
| 6 | Yong-Jun | 4.57M | 19.60% | — | 4.57M | — | 4.57M | IN | — | 2024-07-29 | ↗ |
| 7 | Andrew J. Schwab | 2.35M | 10.10% | — | 2.35M | — | — | IN | Delaware | 2024-08-01 | ↗ |
| 8 | Kush Parmar | 2.35M | 10.10% | — | 2.35M | — | — | IN | Delaware | 2024-08-01 | ↗ |
| 9 | Corey Goodman | 1.82M | 7.80% | — | 1.82M | — | 1.82M | HC, IN | Cayman Islands | 2024-08-01 | ↗ |
| 10 | Robert Adelman | 1.82M | 7.80% | — | 1.82M | — | 1.82M | HC, IN | Cayman Islands | 2024-08-01 | ↗ |
| 11 | venBio Global Strategic Fund III, L.P. | 1.82M | 7.80% | — | 1.82M | — | 1.82M | PN | Cayman Islands | 2024-08-01 | ↗ |
| 12 | venBio Global Strategic GP III, L.P. | 1.82M | 7.80% | — | 1.82M | — | 1.82M | HC, PN | Cayman Islands | 2024-08-01 | ↗ |
| 13 | Koh, Bong | 1.61M | 6.90% | — | 1.61M | — | 1.61M | IN | Delaware | 2024-08-01 | ↗ |
| 14 | Shah, Nimish | 1.61M | 6.90% | — | 1.61M | — | 1.61M | IN | Delaware | 2024-08-01 | ↗ |
| 15 | VHCP Co-Investment Holdings III, LLC | 1.61M | 6.90% | — | 1.61M | — | 1.61M | OO | Delaware | 2024-08-01 | ↗ |
| 16 | VHCP Management EG, LLC | 1.61M | 6.90% | — | 1.61M | — | 1.61M | OO | Delaware | 2024-08-01 | ↗ |
| 17 | VHCP Management III, LLC | 1.61M | 6.90% | — | 1.61M | — | 1.61M | OO | Delaware | 2024-08-01 | ↗ |
| 18 | Venrock Healthcare Capital Partners EG, L.P. | 1.61M | 6.90% | — | 1.61M | — | 1.61M | PN | Delaware | 2024-08-01 | ↗ |
| 19 | Venrock Healthcare Capital Partners III, L.P. | 1.61M | 6.90% | — | 1.61M | — | 1.61M | PN | Delaware | 2024-08-01 | ↗ |
| 20 | GC Cell Corporation | 1.26M | 5.40% | — | 1.26M | — | 1.26M | CO | — | 2024-07-29 | ↗ |
| 21 | 5AM Opportunities II (GP), LLC | 1.18M | 5.10% | — | 1.18M | — | — | OO | Delaware | 2024-08-01 | ↗ |
| 22 | 5AM Opportunities II, L.P. | 1.18M | 5.10% | — | 1.18M | — | — | PN | Delaware | 2024-08-01 | ↗ |
| 23 | 5AM Partners VI, LLC | 1.17M | 5.00% | — | 1.17M | — | — | OO | Delaware | 2024-08-01 | ↗ |
| 24 | 5AM Ventures VI, L.P. | 1.17M | 5.00% | — | 1.17M | — | — | PN | Delaware | 2024-08-01 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
7
-27 vs prev Q
New positions
5
Closed positions
32
Increased
5
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | REVELATION CAPITAL MANAGEMENT, LLC | 299.3K +299.3K (+100.0%) | 1.28B +1.3B (+100.0%) | 1.22% +1.223 pp | 1.54% +1.538 pp | USD4.29 +0.0% | 1 qtrs NEW |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 9.85M +— (+0.0%) | 42.27M +14.0M (+49.5%) | 40.25% -0.170 pp | 0.43% +0.085 pp | USD15.45 -72.2% | 6 qtrs — |
| 3 | 5AM VENTURE MANAGEMENT, LLC | 2.35M +— (+0.0%) | 10.10M +3.3M (+49.5%) | 9.61% -0.041 pp | 3.17% +0.700 pp | USD15.45 -72.2% | 6 qtrs — |
| 4 | VR ADVISER, LLC | 1.61M +— (+0.0%) | 6.91M +2.3M (+49.5%) | 6.57% -0.028 pp | 0.34% +0.081 pp | USD15.45 -72.2% | 6 qtrs — |
| 5 | VENBIO PARTNERS LLC | 648.5K -500.5K (-43.6%) | 2.78M -515.5K (-15.6%) | 2.65% -2.064 pp | 1.29% -0.583 pp | USD15.45 -72.2% | 6 qtrs — |
| 6 | FRANKLIN RESOURCES INC | 520.3K +— (+0.0%) | 2.23M +738.9K (+49.5%) | 2.13% -0.009 pp | 0.00% +0.000 pp | USD15.45 -72.2% | 6 qtrs — |
| 7 | VANGUARD GROUP INC | 246.0K +86.9K (+54.6%) | 1.06M +598.7K (+131.1%) | 1.00% +0.352 pp | 0.00% +0.000 pp | USD11.40 -62.4% | 6 qtrs — |
| 8 | MILLENNIUM MANAGEMENT LLC | 217.1K -45.1K (-17.2%) | 931.3K +178.9K (+23.8%) | 0.89% -0.189 pp | 0.00% +0.000 pp | USD1.51 +184.1% | 3 qtrs — |
| 9 | BLACKROCK, INC. | 212.5K -81.9K (-27.8%) | 911.8K +66.8K (+7.9%) | 0.87% -0.340 pp | 0.00% +0.000 pp | USD12.56 -65.8% | 6 qtrs — |
| 10 | WELLINGTON MANAGEMENT GROUP LLP | 194.1K +— (+0.0%) | 832.7K +275.6K (+49.5%) | 0.79% -0.003 pp | 0.00% +0.000 pp | USD15.45 -72.2% | 6 qtrs — |
| 11 | TWO SIGMA INVESTMENTS, LP | 144.9K +124.5K (+611.4%) | 621.5K +563.0K (+963.3%) | 0.59% +0.508 pp | 0.00% +0.001 pp | USD3.90 +10.0% | 3 qtrs — |
| 12 | RENAISSANCE TECHNOLOGIES LLC | 116.2K +37.1K (+46.8%) | 498.5K +271.3K (+119.5%) | 0.47% +0.150 pp | 0.00% +0.001 pp | USD3.32 +29.2% | 2 qtrs — |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 101.1K -9.8K (-8.8%) | 434.1K +115.6K (+36.3%) | 0.41% -0.042 pp | 0.00% +0.000 pp | USD12.49 -65.7% | 6 qtrs — |
| 14 | ALYESKA INVESTMENT GROUP, L.P. | 100.0K +— (+0.0%) | 429.0K +142.0K (+49.5%) | 0.41% -0.002 pp | 0.00% +0.000 pp | USD15.45 -72.2% | 6 qtrs — |
| 15 | MARSHALL WACE, LLP | 79.6K +79.6K (+100.0%) | 341.3K +341.3K (+100.0%) | 0.33% +0.325 pp | 0.00% +0.000 pp | USD4.29 +0.0% | 3 qtrs — |
| 16 | JANE STREET GROUP, LLC | 40.7K +40.7K (+100.0%) | 174.5K +174.5K (+100.0%) | 0.17% +0.166 pp | 0.00% +0.000 pp | USD4.29 +0.0% | 3 qtrs — |
| 17 | UBS GROUP AG | 36.9K +15.7K (+74.4%) | 158.2K +97.5K (+160.7%) | 0.15% +0.064 pp | 0.00% +0.000 pp | USD4.09 +4.9% | 6 qtrs — |
| 18 | STATE STREET CORP | 35.8K -24.0K (-40.1%) | 153.7K -18.0K (-10.5%) | 0.15% -0.099 pp | 0.00% +0.000 pp | USD12.50 -65.7% | 6 qtrs — |
| 19 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 35.0K +— (+0.0%) | 150.2K +49.7K (+49.5%) | 0.14% -0.001 pp | 0.00% +0.001 pp | USD1.51 +184.1% | 3 qtrs — |
| 20 | SCIENTECH RESEARCH LLC | 27.8K +27.8K (+100.0%) | 119.1K +119.1K (+100.0%) | 0.11% +0.113 pp | 0.07% +0.075 pp | USD4.29 +0.0% | 1 qtrs NEW |
| 21 | MORGAN STANLEY | 27.1K -15.8K (-36.8%) | 116.1K -6.8K (-5.5%) | 0.11% -0.065 pp | 0.00% +0.000 pp | USD9.90 -56.7% | 6 qtrs — |
| 22 | OMERS ADMINISTRATION CORP | 21.1K +21.1K (+100.0%) | 90.5K +90.5K (+100.0%) | 0.09% +0.086 pp | 0.00% +0.001 pp | USD4.29 +0.0% | 1 qtrs NEW |
| 23 | GOLDMAN SACHS GROUP INC | 12.1K -37.7K (-75.8%) | 51.7K -91.1K (-63.8%) | 0.05% -0.155 pp | 0.00% +0.000 pp | USD5.67 -24.3% | 6 qtrs — |
| 24 | PRELUDE CAPITAL MANAGEMENT, LLC | 10.7K -3.6K (-25.2%) | 45.9K +4.8K (+11.7%) | 0.04% -0.015 pp | 0.00% +0.000 pp | USD2.87 +49.5% | 2 qtrs — |
| 25 | RUSSELL INVESTMENTS GROUP, LTD. | 5.5K +— (+0.0%) | 23.6K +7.8K (+49.5%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD1.51 +184.1% | 3 qtrs — |
| 26 | FMR LLC | 3.6K -1.4K (-27.7%) | 15.3K +1.1K (+8.1%) | 0.01% -0.006 pp | 0.00% +0.000 pp | USD1.81 +137.0% | 6 qtrs — |
| 27 | WELLS FARGO & COMPANY/MN | 1.5K -200.0 (-11.8%) | 6.4K +1.6K (+31.9%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD10.05 -57.3% | 6 qtrs — |
| 28 | TOWER RESEARCH CAPITAL LLC (TRC) | 1.1K -8.9K (-88.9%) | 4.7K -23.9K (-83.5%) | 0.00% -0.036 pp | 0.00% -0.001 pp | USD3.13 +37.1% | 6 qtrs — |
| 29 | BNP PARIBAS ARBITRAGE, SNC | 542.00 -118.0K (-99.5%) | 2.3K -337.9K (-99.3%) | 0.00% -0.484 pp | 0.00% 0.000 pp | USD2.91 +47.4% | 6 qtrs — |
| 30 | MARK SHEPTOFF FINANCIAL PLANNING, LLC | 400.00 +— (+0.0%) | 1.7K +568.0 (+49.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD15.45 -72.2% | 6 qtrs — |
| 31 | ROYAL BANK OF CANADA | 339.00 -501.0 (-59.6%) | 1.0K -2.0K (-66.7%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD7.45 -42.4% | 6 qtrs — |
| 32 | JPMORGAN CHASE & CO | 187.00 -3.8K (-95.3%) | 802.00 -10.7K (-93.0%) | 0.00% -0.016 pp | 0.00% +0.000 pp | USD4.75 -9.7% | 6 qtrs — |
| 33 | BANK OF AMERICA CORP /DE/ | 113.00 -16.0K (-99.3%) | 484.00 -45.9K (-99.0%) | 0.00% -0.066 pp | 0.00% +0.000 pp | USD6.73 -36.3% | 6 qtrs — |
| 34 | ADVISOR GROUP HOLDINGS, INC. | 32.00 +32.0 (+100.0%) | 137.00 +137.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.28 +0.2% | 1 qtrs NEW |
| 35 | XTX TOPCO LTD | — -48.0K (-100.0%) | — -137.7K (-100.0%) | 0.00% -0.197 pp | 0.00% -0.007 pp | USD— | 2 qtrs SOLD |
| 36 | HRT FINANCIAL LP | — -27.0K (-100.0%) | — -77.0K (-100.0%) | 0.00% -0.111 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 37 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | — -944.0 (-100.0%) | — -2.7K (-100.0%) | 0.00% -0.004 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 38 | QUBE RESEARCH & TECHNOLOGIES LTD | — -25.6K (-100.0%) | — -73.3K (-100.0%) | 0.00% -0.105 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 39 | GF FUND MANAGEMENT CO. LTD. | — -510.0 (-100.0%) | — -1.5K (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 40 | EVERSOURCE WEALTH ADVISORS, LLC | — -159.0 (-100.0%) | — -456.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 41 | CITIGROUP INC | — -105.6K (-100.0%) | — -303.0K (-100.0%) | 0.00% -0.433 pp | 0.00% 0.000 pp | USD— | 6 qtrs SOLD |
| 42 | CITADEL ADVISORS LLC | — -798.4K (-100.0%) | — -2.3M (-100.0%) | 0.00% -3.275 pp | 0.00% 0.000 pp | USD— | 6 qtrs SOLD |
| 43 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | — -4.3K (-100.0%) | — -12.3K (-100.0%) | 0.00% -0.018 pp | 0.00% -0.001 pp | USD— | 5 qtrs SOLD |
| 44 | BARCLAYS PLC | — -19.6K (-100.0%) | — -303.1K (-100.0%) | 0.00% -0.081 pp | 0.00% 0.000 pp | USD— | 6 qtrs SOLD |
| 45 | LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | — -39.1K (-100.0%) | — -112.3K (-100.0%) | 0.00% -0.161 pp | 0.00% -0.007 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 37 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Simplify Propel Opportunities ETF SURI | 1.26% | 977.1K | 2.82% |
| 2 | iShares Micro-Cap ETF IWC | 0.01% | 152.2K | 0.60% |
| 3 | U.S. Micro Cap Portfolio ETF DFMC | 0.00% | 263.5K | 0.43% |
| 4 | iShares Russell 2000 BuyWrite ETF IWMW | 0.00% | 946.78 | 0.39% |
| 5 | iShares Russell 2000 ETF IWM | 0.00% | 1.38M | 0.19% |
| 6 | iShares U.S. Small Cap Index ETF (CAD-Hedged) XSU.TO | 0.00% | 9.0K | 0.36% |
| 7 | Global X - Russell 2000 ETF RSSL | 0.00% | 21.0K | 0.08% |
| 8 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.00% | 4.5K | 0.25% |
| 9 | iShares Russell 2000 Value ETF IWN | 0.00% | 198.4K | 0.24% |
| 10 | Dimensional - US Core Equity 1 ETF DCOR | 0.00% | 28.6K | 0.14% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.75
Bullish
Ratio by volume
3.00
Bullish
Buys
7
Sells
4
Shares acquired
997.0K
Shares disposed
21.8K
Cash buys
—
Cash sales
—
Net activity
+975,127
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-10 | Huston Thad Allen | Officer | A-Award | A | Common Stock | 220,000 | 0.00 | — | 220,000 | D | ↗ |
| 2026-02-18 | Sorg Elaine K. | Director | A-Award | A | Director Stock Option (Right to Buy) | 27,500 | 4.15 | 114.1K | 27,500 | D | ↗ |
| 2026-02-18 | Huston Thad Allen | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-02-15 | Raymon Heather | Officer | F-InKind | D | Common Stock | 1,521 | 4.00 | 6.1K | 151,323 | D | ↗ |
| 2026-02-15 | Horan Christopher | Officer | F-InKind | D | Common Stock | 2,187 | 4.00 | 8.7K | 300,452 | D | ↗ |
| 2026-02-15 | Bush Jennifer | Officer | A-Award | A | Common Stock | 117,300 | 0.00 | — | 350,225 | D | ↗ |
| 2026-02-15 | Banerjee Subhashis | Officer | A-Award | A | Common Stock | 102,000 | 0.00 | — | 152,000 | D | ↗ |
| 2026-02-15 | Aslan Fred | Director / Officer | F-InKind | D | Common Stock | 14,600 | 4.00 | 58.4K | 1,562,198 | D | ↗ |
| 2025-12-15 | Aslan Fred | Director / Officer | S-Sale | D | Common Stock | 3,187 | 6.00 | 19.1K | 1,209,948 | D | ↗ |
| 2025-12-12 | Raymon Heather | Officer | D-Return | D | Employee Stock Option (Right to Buy) | 14,819 | 5.01 | 74.2K | 0 | D | ↗ |
| 2025-12-12 | Horan Christopher | Officer | D-Return | D | Employee Stock Option (Right to Buy) | 9,119 | 5.01 | 45.7K | 0 | D | ↗ |
| 2025-12-12 | Bush Jennifer | Officer | A-Award | A | Common Stock | 84,877 | 0.00 | — | 232,925 | D | ↗ |
| 2025-12-12 | Aslan Fred | Director / Officer | D-Return | D | Employee Stock Option (Right to Buy) | 113,999 | 13.47 | 1.54M | 0 | D | ↗ |
| 2025-11-17 | Aslan Fred | Director / Officer | S-Sale | D | Common Stock | 6,375 | 3.38 | 21.5K | 343,999 | D | ↗ |
| 2025-11-15 | Raymon Heather | Officer | F-InKind | D | Common Stock | 1,375 | 3.25 | 4.5K | 39,591 | D | ↗ |
| 2025-11-15 | Krishnamohan Neha | Officer | F-InKind | D | Common Stock | 3,490 | 3.25 | 11.3K | 99,356 | D | ↗ |
| 2025-11-15 | Horan Christopher | Officer | F-InKind | D | Common Stock | 1,899 | 3.25 | 6.2K | 78,183 | D | ↗ |
| 2025-11-15 | Bush Jennifer | Officer | F-InKind | D | Common Stock | 3,055 | 3.25 | 9.9K | 148,048 | D | ↗ |
| 2025-11-15 | Aslan Fred | Director / Officer | F-InKind | D | Common Stock | 6,347 | 3.25 | 20.6K | 350,374 | D | ↗ |
| 2025-10-17 | Aslan Fred | Director / Officer | S-Sale | D | Common Stock | 25,500 | 6.00 | 153.0K | 356,721 | D | ↗ |
| 2025-08-15 | Raymon Heather | Officer | F-InKind | D | Common Stock | 1,639 | 2.75 | 4.5K | 40,966 | D | ↗ |
| 2025-08-15 | Krishnamohan Neha | Officer | F-InKind | D | Common Stock | 5,813 | 2.75 | 16.0K | 102,846 | D | ↗ |
| 2025-08-15 | Horan Christopher | Officer | F-InKind | D | Common Stock | 3,577 | 2.75 | 9.8K | 80,082 | D | ↗ |
| 2025-08-15 | Bush Jennifer | Officer | F-InKind | D | Common Stock | 6,409 | 2.75 | 17.6K | 151,103 | D | ↗ |
| 2025-08-15 | Aslan Fred | Director / Officer | S-Sale | D | Common Stock | 25,500 | 2.73 | 69.6K | 386,693 | D | ↗ |
| 2025-06-24 | Stoppel Laura | Director | A-Award | A | Director Stock Option (Right to Buy) | 13,750 | 1.61 | 22.1K | 13,750 | D | ↗ |
| 2025-06-24 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Director Stock Option (Right to Buy) | 13,750 | 1.61 | 22.1K | 13,750 | I | ↗ |
| 2025-06-24 | Miralles Gines Diego | Director | A-Award | A | Director Stock Option (Right to Buy) | 13,750 | 1.61 | 22.1K | 13,750 | D | ↗ |
| 2025-06-24 | MOORE ALISON | Director | A-Award | A | Director Stock Option (Right to Buy) | 13,750 | 1.61 | 22.1K | 13,750 | D | ↗ |
| 2025-06-24 | HOUGEN ELIZABETH L | Director | A-Award | A | Director Stock Option (Right to Buy) | 13,750 | 1.61 | 22.1K | 13,750 | D | ↗ |
| 2025-06-24 | DANIELS BRIAN | Director | A-Award | A | Director Stock Option (Right to Buy) | 13,750 | 1.61 | 22.1K | 13,750 | D | ↗ |
| 2025-06-24 | Baker Daniel G. | Director | A-Award | A | Director Stock Option (Right to Buy) | 13,750 | 1.61 | 22.1K | 13,750 | D | ↗ |
| 2025-05-15 | Raymon Heather | Officer | F-InKind | D | Common Stock | 745 | 2.13 | 1.6K | 42,605 | D | ↗ |
| 2025-05-15 | Krishnamohan Neha | Officer | F-InKind | D | Common Stock | 1,341 | 2.13 | 2.9K | 108,659 | D | ↗ |
| 2025-05-15 | Horan Christopher | Officer | F-InKind | D | Common Stock | 1,341 | 2.13 | 2.9K | 83,659 | D | ↗ |
| 2025-05-15 | Bush Jennifer | Officer | F-InKind | D | Common Stock | 1,937 | 2.13 | 4.1K | 157,512 | D | ↗ |
| 2025-05-15 | Aslan Fred | Director / Officer | F-InKind | D | Common Stock | 4,472 | 2.13 | 9.5K | 412,193 | D | ↗ |
| 2025-04-08 | Banerjee Subhashis | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 80,000 | 1.92 | 153.6K | 80,000 | D | ↗ |
| 2025-03-05 | Aslan Fred | Director / Officer | A-Award | A | Common Stock | 200,000 | 0.00 | — | 416,665 | D | ↗ |
| 2025-02-26 | Raymon Heather | Officer | A-Award | A | Common Stock | 33,350 | 0.00 | — | 43,350 | D | ↗ |
| 2025-02-26 | Krishnamohan Neha | Officer | A-Award | A | Common Stock | 60,000 | 0.00 | — | 110,000 | D | ↗ |
| 2025-02-26 | Horan Christopher | Officer | A-Award | A | Common Stock | 60,000 | 0.00 | — | 85,000 | D | ↗ |
| 2025-02-26 | Graef Thorsten | Officer | A-Award | A | Common Stock | 60,000 | 0.00 | — | 80,000 | D | ↗ |
| 2025-02-26 | Bush Jennifer | Officer | A-Award | A | Common Stock | 86,650 | 0.00 | — | 159,449 | D | ↗ |
| 2025-01-28 | Baker Daniel G. | Director | A-Award | A | Director Stock Option (Right to Buy) | 27,500 | 5.56 | 152.9K | 27,500 | D | ↗ |
| 2024-10-21 | MOORE ALISON | Director | A-Award | A | Director Stock Option (Right to Buy) | 27,500 | 10.48 | 288.2K | 27,500 | D | ↗ |
| 2024-09-12 | Raymon Heather | Officer | A-Award | A | Common Stock | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2024-09-12 | Krishnamohan Neha | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2024-09-12 | Horan Christopher | Officer | A-Award | A | Common Stock | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2024-09-12 | Graef Thorsten | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2024-09-12 | Bush Jennifer | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 72,799 | — | ↗ |
| 2024-07-22 | venBio Global Strategic Fund III, L.P. | 10% Owner | C-Conversion | A | Common Stock | 214,692 | 0.00 | — | 1,058,284 | — | ↗ |
| 2024-07-22 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% Owner | C-Conversion | A | Common Stock | 145,089 | 0.00 | — | 145,089 | — | ↗ |
| 2024-07-22 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | J-Other | A | Common Stock | 138,506 | 10.20 | 1.41M | 138,506 | — | ↗ |
| 2024-07-22 | Huh Yong-Jun | Director | J-Other | A | Common Stock | 294,117 | 10.20 | 3.00M | 1,640,234 | — | ↗ |
| 2024-07-22 | GC Corp. | 10% Owner | C-Conversion | A | Common Stock | 667,185 | 0.00 | — | 1,016,022 | — | ↗ |
| 2024-07-22 | Aslan Fred | Director / Officer | A-Award | A | Common Stock | 228,905 | 0.00 | — | 228,905 | — | ↗ |
| 2024-07-22 | 5AM Partners VI, LLC | 10% Owner | P-Purchase | A | Common Stock | 833,333 | 12.00 | 10.00M | 1,182,054 | — | ↗ |
| 2024-07-18 | venBio Global Strategic Fund III, L.P. | 10% Owner | — | D | Series B Preferred Stock | 214,692 | 0.00 | — | 0 | — | ↗ |
| 2024-07-18 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% Owner | — | D | Series B Preferred Stock | 145,089 | 0.00 | — | 0 | — | ↗ |
| 2024-07-18 | Stoppel Laura | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-07-18 | Raymon Heather | Officer | — | D | Employee Stock Option (Right to Buy) | 10,259 | 13.47 | 138.2K | 0 | — | ↗ |
| 2024-07-18 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | — | I | Series B Preferred Stock | 53,673 | 0.00 | — | 0 | — | ↗ |
| 2024-07-18 | Miralles Gines Diego | Director | — | D | Director Stock Option (right to buy) | 12,995 | 5.18 | 67.3K | 0 | — | ↗ |
| 2024-07-18 | Krishnamohan Neha | Officer | — | D | Employee Stock Option (Right to Buy) | 102,599 | 13.47 | 1.38M | 0 | — | ↗ |
| 2024-07-18 | Huh Yong-Jun | Director | — | I | Common Stock | 0 | 0.00 | — | 348,837 | — | ↗ |
| 2024-07-18 | Horan Christopher | Officer | — | D | Employee Stock Option (Right to Buy) | 20,519 | 13.47 | 276.4K | 0 | — | ↗ |
| 2024-07-18 | HOUGEN ELIZABETH L | Director | — | D | Director Stock Option (right to buy) | 3,419 | 13.47 | 46.1K | 0 | — | ↗ |
| 2024-07-18 | Graef Thorsten | Officer | — | D | Employee Stock Option (Right to Buy) | 15,959 | 13.47 | 215.0K | 0 | — | ↗ |
| 2024-07-18 | GC Corp. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 348,837 | — | ↗ |
| 2024-07-18 | DANIELS BRIAN | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-07-18 | Bush Jennifer | Officer | — | D | Common Stock | 0 | 0.00 | — | 22,799 | — | ↗ |
| 2024-07-18 | Bessen Laura | Director | — | D | Director Stock Option (Right to Buy) | 13,679 | 5.01 | 68.5K | 0 | — | ↗ |
| 2024-07-18 | Aslan Fred | Director / Officer | — | D | Employee Stock Option (Right to Buy) | 26,450 | 5.18 | 137.0K | 0 | — | ↗ |
| 2024-07-18 | 5AM Partners VI, LLC | 10% Owner | — | I | Series A Preferred Stock | 843,592 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
24.72M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fred Aslan | President, Chief Executive Officer & Director | 1M | — |
| Jennifer Kinsbruner Bush | Chief Operating Officer | 839.2K | female |
| Christopher Horan | Chief Technical Operations Officer | 777.6K | male |
| Peter Flynn | Co-Founder & Strategic Advisor | 499.4K | — |
| Heather Raymon | Senior Vice President of Research & Early Development | — | — |
| Nicholas Veomett | Vice President of Corporate Development | — | — |
| Subhashis Banerjee | Chief Medical Officer | — | — |
| Andrew Cronauer | VP, General Counsel & Corporate Secretary | — | male |
| Thad Huston | CFO and Principal Financial & Accounting Officer | — | male |
| Benjamin Dewees | Senior Vice President of Regulatory Affairs | — | male |
| David Moriarty | Senior Vice President of Clinical Operations | — | — |
| Feng Xu | Senior Vice President of Biometrics | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ARTV
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
